Use of recombinant activated factor vii in bleeding lung transplant patients undergoing perioperative ecmo therapy “2279

HIGHLIGHTS

SUMMARY

Data on the efficacy and safety of perioperative rFVIIa administration are scarce, particularly in patients undergoing ECMO therapy. This study aimed to retrospectively investigate lung transplant patients on perioperative ECMO support who received rFVIIa for intractable bleeding. Specifically, the authors evaluated (i) the efficacy of rFVIIa in terms of bleeding control, (ii) the fulfillment of recommended preconditions before rFVIIa administration, and_(iii) the occurrence of thromboembolic events following rFVIIa administration. The authors found that most of the recoman acceptable efficacy and safety profile of rFVIIa in this context. mendedTo hemostatic preconditions (84%) were fulfilled . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.